Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWH NASDAQ:ESPR NASDAQ:IVA NASDAQ:OLMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.67-2.9%$0.55$0.26▼$1.02$136.98M1.17165,148 shs72,026 shsESPREsperion Therapeutics$2.84+1.8%$1.82$0.69▼$3.94$562.53M0.895.85 million shs4.55 million shsIVAInventiva$5.61-2.8%$4.15$1.53▼$6.50$536.66M0.6971,042 shs128,196 shsOLMAOlema Pharmaceuticals$7.77-2.9%$5.47$2.86▼$13.93$533.29M1.92938,510 shs1.35 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness0.00%-7.59%+4.69%+126.73%-31.63%ESPREsperion Therapeutics0.00%+5.97%+37.20%+142.74%+63.22%IVAInventiva0.00%+0.72%+32.94%+64.52%+150.45%OLMAOlema Pharmaceuticals0.00%-6.50%+47.72%+86.33%-37.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.67-2.9%$0.55$0.26▼$1.02$136.98M1.17165,148 shs72,026 shsESPREsperion Therapeutics$2.84+1.8%$1.82$0.69▼$3.94$562.53M0.895.85 million shs4.55 million shsIVAInventiva$5.61-2.8%$4.15$1.53▼$6.50$536.66M0.6971,042 shs128,196 shsOLMAOlema Pharmaceuticals$7.77-2.9%$5.47$2.86▼$13.93$533.29M1.92938,510 shs1.35 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness0.00%-7.59%+4.69%+126.73%-31.63%ESPREsperion Therapeutics0.00%+5.97%+37.20%+142.74%+63.22%IVAInventiva0.00%+0.72%+32.94%+64.52%+150.45%OLMAOlema Pharmaceuticals0.00%-6.50%+47.72%+86.33%-37.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 1.00SellN/AN/AESPREsperion Therapeutics 2.80Moderate Buy$7.00146.48% UpsideIVAInventiva 2.83Moderate Buy$14.83164.41% UpsideOLMAOlema Pharmaceuticals 2.83Moderate Buy$24.00208.88% UpsideCurrent Analyst Ratings BreakdownLatest AAWH, OLMA, IVA, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/3/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/14/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$28.00 ➝ $29.008/12/2025AAWHAscend WellnessZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/12/2025OLMAOlema PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $21.008/11/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell6/17/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.26$0.10 per share6.64$0.69 per share0.97ESPREsperion Therapeutics$332.31M1.72$0.02 per share116.12($1.97) per share-1.44IVAInventiva$9.20M58.35N/AN/A($1.21) per share-4.64OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.42N/AN/AN/A-15.47%-72.18%-9.55%N/AESPREsperion Therapeutics-$51.74M-$0.49N/AN/A62.67-35.84%-0.91%-28.41%11/6/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)Latest AAWH, OLMA, IVA, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q2 2025IVAInventiva-$0.41N/AN/AN/AN/AN/A8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80ESPREsperion TherapeuticsN/A1.150.76IVAInventivaN/A0.920.92OLMAOlema Pharmaceuticals0.0111.0911.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.31%ESPREsperion Therapeutics47.39%IVAInventiva19.06%OLMAOlema Pharmaceuticals91.78%Insider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.38%ESPREsperion Therapeutics1.70%IVAInventiva32.00%OLMAOlema Pharmaceuticals16.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.44 million166.44 millionNot OptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableAAWH, OLMA, IVA, and ESPR HeadlinesRecent News About These CompaniesCubist Systematic Strategies LLC Buys 67,682 Shares of Olema Pharmaceuticals, Inc. $OLMASeptember 14 at 3:13 AM | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $24.00 Consensus Price Target from BrokeragesSeptember 14 at 2:34 AM | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Rating Upgraded by Zacks ResearchSeptember 13 at 7:21 AM | marketbeat.comOLMA Stock Soars 47% in September So Far on Second PFE DealSeptember 12 at 11:41 AM | zacks.comOlema Pharmaceuticals (NASDAQ:OLMA) Upgraded at Zacks ResearchSeptember 12 at 2:39 AM | americanbankingnews.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 11 at 4:39 AM | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Down 7.2% - Should You Sell?September 10, 2025 | marketbeat.comInvesco Ltd. Purchases 34,362 Shares of Olema Pharmaceuticals, Inc. $OLMASeptember 10, 2025 | marketbeat.comPDT Partners LLC Makes New Investment in Olema Pharmaceuticals, Inc. $OLMASeptember 8, 2025 | marketbeat.comHC Wainwright Issues Positive Outlook for OLMA EarningsSeptember 7, 2025 | marketbeat.comHC Wainwright Has Positive Forecast for OLMA Q3 EarningsSeptember 6, 2025 | americanbankingnews.comOppenheimer Reaffirms "Outperform" Rating for Olema Pharmaceuticals (NASDAQ:OLMA)September 5, 2025 | marketbeat.comBVF Inc. IL Sells 420,000 Shares of Olema Pharmaceuticals, Inc. $OLMASeptember 5, 2025 | marketbeat.comOlema Pharmaceuticals, Inc. $OLMA is Bain Capital Life Sciences Investors LLC's 8th Largest PositionSeptember 5, 2025 | marketbeat.comPfizer collaboration with Olema may spark future bidding war - analystSeptember 3, 2025 | msn.comOlema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement PlanSeptember 3, 2025 | quiverquant.comQOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 | globenewswire.comOlema Pharmaceuticals, Inc. $OLMA Shares Sold by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.comOlema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerSeptember 2, 2025 | globenewswire.comNuveen LLC Acquires New Holdings in Olema Pharmaceuticals, Inc. $OLMASeptember 2, 2025 | marketbeat.comWellington Management Group LLP Reduces Stake in Olema Pharmaceuticals, Inc. $OLMAAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025AAWH, OLMA, IVA, and ESPR Company DescriptionsAscend Wellness OTC:AAWH$0.67 -0.02 (-2.87%) As of 09/12/2025 03:58 PM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.Esperion Therapeutics NASDAQ:ESPR$2.84 +0.05 (+1.79%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.86 +0.02 (+0.67%) As of 09/12/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Inventiva NASDAQ:IVA$5.60 -0.17 (-2.86%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Olema Pharmaceuticals NASDAQ:OLMA$7.77 -0.23 (-2.88%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$8.06 +0.29 (+3.73%) As of 09/12/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
